Trial intelligence / Profile preview

Antineoplastons A10 and AS2-1 in Adenocarcinoma of Unknown Primary

NCT00003526Phase 2Terminated

Sponsor
Burzynski Research Institute
Start
Mar 1996
Primary completion
Feb 2005
Modality
Peptides, Small Molecules
Countries
1
01

Overview

A Phase 2 trial of antineoplaston A10, antineoplaston AS2-1 in Adenocarcinoma, sponsored by Burzynski Research Institute. Started Mar 1996; status: terminated.

02

Drugs

antineoplaston A10antineoplaston AS2-1
03

Conditions

Adenocarcinoma

Beyond the preview

Go deeper on NCT00003526.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00003526.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call